The impact of CVB3 infection on host cell biology

Current Topics in Microbiology and Immunology

Volumn 323, Issue , 2008, Pages 177-198

  Marchant, D ^a   Si, X ^a   Luo, H ^a   McManus, B ^a   Yang, D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CELL PROTEIN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; DECAY ACCELERATING FACTOR; FOMIVIRSEN; JANUS KINASE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; PLECONARIL; PROTEASOME; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RIBAVIRIN; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UBIQUITIN; PROTEIN KINASE;

5' UNTRANSLATED REGION; ANTISENSE THERAPY; CELL DEATH; CELL SURVIVAL; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; COXSACKIE VIRUS B3; COXSACKIE VIRUS INFECTION; CYTOLOGY; CYTOMEGALOVIRUS INFECTION; CYTOPATHOGENIC EFFECT; ENZYME ACTIVATION; HEART MUSCLE; HEMOLYTIC ANEMIA; HOST CELL; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RESPONSE; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; PROGENY; PROTEIN INTERACTION; REVIEW; VIRUS ENTRY; VIRUS MYOCARDITIS; VIRUS REPLICATION; ANIMAL; ENTEROVIRUS; INFLAMMATION; METABOLISM; MYOCARDITIS; PHYSIOLOGY; SIGNAL TRANSDUCTION; VIROLOGY;

ANIMALS; COXSACKIEVIRUS INFECTIONS; ENTEROVIRUS B, HUMAN; HUMANS; INFLAMMATION; MYOCARDITIS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASES; SIGNAL TRANSDUCTION; UBIQUITIN;

EID: 43649087292     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-75546-3_8     Document Type: Review

References (80)

1. Arola A, Kalimo H, Ruuskanen O, Hyypia T (1995) Experimental myocarditis induced by two different coxsackievirus B3 variants: aspects of pathogenesis and comparison of diagnostic methods. J Med Virol 47:251-259
2. Buck CB, Thompson CD, Roberts JN, et al (2006) Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2:e69
3. Calandria C, Irurzun A, Barco A, Carrasco L (2004) Individual expression of poliovirus 2Apro and 3Cpro induces activation of caspase-3 and PARP cleavage in HeLa cells. Virus Res 104:39-49
4. Carthy CM, Granville DJ, Watson KA, Anderson DR, Wilson JE, Yang D, Hunt DW, McManus BM (1998) Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells. J Virol 72:7669-7675
5. Carthy CM, Yanagawa B, Luo H, Granville DJ, Yang D, Cheung P, Cheung C, Esfandiarei M, Rudin CM, Thompson CB, Hunt DW, McManus BM (2003) Bcl-2 and Bcl-xL overexpression inhibits cytochrome c release, activation of multiple caspases, and virus release following coxsackievirus B3 infection. Virology 313:147-157
6. Chau D, Yuan J, Zhang H, et al (2007) Coxsackievirus B3 proteases 2A and 3C induce apoptotic cell death through mitochondrial injury and cleavage of eIF4GI but not DAP5/p97/NAT1. Apoptosis 12:513-524
7. Cheung C, Luo H, Yanagawa B, Leong HS, Samarasekera D, Lai JC, Suarez A, Zhang J, McManus BM (2006) Matrix metalloproteinases and tissue inhibitors of metalloproteinases in coxsackievirus-induced myocarditis. Cardiovasc Pathol 15:63-74
8. Cheung P, Zhang M, Yuan J, Chau D, Yanagawa B, McManus B, Yang D (2002) Specific interactions of HeLa cell proteins with Coxsackievirus B3 RNA: La autoantigen binds differentially to multiple sites within the 5′ untranslated region. Virus Res 90:23-36
9. Cheung PK, Yuan J, Zhang HM, Chau D, Yanagawa B, Suarez A, McManus B, Yang D (2005) Specific interactions of mouse organ proteins with the 5′ untranslated region of coxsackievirus B3: potential determinants of viral tissue tropism. J Med Virol 77:414-424
10. Chung SK, Kim JY, Kim IB, Park SI, Paek KH, Nam JH (2005) Internalization and trafficking mechanisms of coxsackievirus B3 in HeLa cells. Virology 333:31-40
11. Coyne CB, Bergelson JM (2006) Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. Cell 124:119-131
12. Cunningham KA, Chapman NM, Carson SD (2003) Caspase-3 activation and ERK phosphorylation during CVB3 infection of cells: influence of the coxsackievirus and adenovirus receptor and engineered variants. Virus Res 92:179-186
13. Dasgupta A, Das S, Izumi R, Venkatesan A, Barat B (2004) Targeting internal ribosome entry site (IRES)-mediated translation to block hepatitis C and other RNA viruses. FEMS Microbiol Lett 234:189-199
14. De Clercq E (2002) Strategies in the design of antiviral drugs. Nat Rev Drug Discov 1:13-25
15. Dildine SL, Semler BL (1992) Conservation of RNA-protein interactions among picornaviruses. J Virol 66:4364-4376
16. Elkington PT, Friedland JS (2006) Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61:259-266
17. Esfandiarei M, Luo H, Yanagawa B, Suarez A, Dabiri D, Zhang J, McManus BM (2004) Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol 78:4289-4298
18. Fauci AS (2006) Emerging and re-emerging infectious diseases: influenza as a prototype of the host-pathogen balancing act. Cell 124:665-670
19. Florea NR, Maglio D, Nicolau DP (2003) Pleconaril, a novel antipicornaviral agent. Pharmacotherapy 23:339-348
20. Gilbert BE, Knight V (1986) Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 30:201-205
21. Glickman MH, Ciechanover A (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428
22. Goodfellow IG, Evans DJ, Blom AM, Kerrigan D, Miners JS, Morgan BP, Spiller OB (2005) Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors. J Virol 79:12016-12024
23. Heim A, Grumbach I, Pring-Akerblom P, Stille-Siegener M, Müller G, Kandolf R, Figulla HR (1997) Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha. Antiviral Res 34:101-111
24. Heymans S, Pauschinger M, De Palma A, Kallwellis-Opara A, Rutschow S, Swinnen M, Vanhoutte D, Gao F, Torpai R, Baker AH, Padalko E, Neyts J, Schultheiss HP, Van de Werf F, Carmeliet P, Pinto YM (2006) Inhibition of urokinase-type plasminogen activator or matrix metalloproteinases prevents cardiac injury and dysfunction during viral myocarditis. Circulation 114:565-573
25. Holmes EC (2003) Molecular clocks and the puzzle of RNA virus origins. J Virol 77:3893-3897
26. Huber M, Selinka HC, Kandolf R (1997) Tyrosine phosphorylation events during coxsackievirus B3 replication. J Virol 71:595-600
27. Huber M, Watson KA, Selinka HC, Carthy CM, Klingel K, McManus BM, Kandolf R (1999) Cleavage of RasGAP and phosphorylation of mitogen-activated protein kinase in the course of coxsackievirus B3 replication. J Virol 73:3587-3594
28. Huber SA, Lodge PA (1984) Coxsackievirus B-3 myocarditis in Balb/c mice. Evidence for autoimmunity to myocyte antigens. Am J Pathol 116:21-29
29. Huber SA, Pfaeffle B (1994) Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J Virol 68:5126-5132
30. Huber SA, Job LP, Auld KR (1982) Influence of sex hormones on Coxsackie B-3 virus infection in Balb/c mice. Cell Immunol 67:173-179 Irie-Sasaki J, Sasaki T, Matsumoto W, Opavsky A, Cheng M, Welstead G, Griffiths E, Krawczyk
31. C, Richardson CD, Aitken K, Iscove N, Koretzky G, Johnson P, Liu P, Rothstein DM, Penninger JM (2001) CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling. Nature 409:349-354
32. Kandolf R, Ameis D, Kirschner P, Canu A, Hofschneider PH (1987) In situ detection of enteroviral genomes in myocardial cells by nucleic acid hybridization: an approach to the diagnosis of viral heart disease. Proc Natl Acad Sci USA 84:6272-6276
33. Kim KS, Hufnagel G, Chapman NM, Tracy S (2001) The group B coxsackieviruses and myocarditis. Rev Med Virol 11:355-368
34. Kim SM, Park JH, Chung SK, Kim JY, Hwang HY, Chung KC, Jo I, Park SI, Nam JH (2004) Coxsackievirus B3 infection induces cyr61 activation via JNK to mediate cell death. J Virol 78:13479-13488
35. Kishimoto C, Crumpacker CS, Abelmann WH (1988) Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets. J Am Coll Cardiol 12:1334-1341
36. Li J, Schwimmbeck PL, Tschope C, Leschka S, Husmann L, Rutschow S, Reichenbach F, Noutsias M, Kobalz U, Poller W, Spillmann F, Zeichhardt H, Schultheiss HP, Pauschinger M (2002) Collagen degradation in a murine myocarditis model: relevance of matrix metalloproteinase in association with inflammatory induction. Cardiovasc Res 56:235-247
37. Lim BK, Nam JH, Gil CO, Yun SH, Choi JH, Kim DK, Jeon ES (2005) Coxsackievirus B3 replication is related to activation of the late extracellular signal-regulated kinase (ERK) signal. Virus Res 113:153-157
38. Lim BK, Choi JH, Nam JH, Gil CO, Shin JO, Yun SH, Kim DK, Jeon ES (2006) Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis. Cardiovasc Res 71:517-526
39. Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P, Gallo R (1992) Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment. Proc Natl Acad Sci U S A 89:11209-11213
40. Liu P, Aitken K, Kong YY, Opavsky MA, Martino T, Dawood F, Wen WH, Kozieradzki I, Bachmaier K, Straus D, Mak TW, Penninger JM (2000) The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med 6:429-434
41. Luo H, Yanagawa B, Zhang J, Luo Z, Zhang M, Esfandiarei M, Carthy C, Wilson JE, Yang D, McManus BM (2002) Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J Virol 76:3365-3373
42. Luo H, Zhang J, Dastvan F, Yanagawa B, Reidy MA, Zhang HM, Yang D, Wilson JE, McManus BM (2003a) Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J Virol 77:1-9
43. Luo H, Zhang J, Cheung C, Suarez A, McManus BM, Yang D (2003b) Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am J Pathol 163:381-385
44. MacLennan C, Dunn G, Huissoon AP, Kumararatne DS, Martin J, O'Leary P, Thompson RA, Osman H, Wood P, Minor P, Wood DJ, Pillay D (2004) Failure to clear persistent vaccine-derived neurovirulent poliovirus infection in an immunodeficient man. Lancet 363:1509-1513
45. Martin AB, Webber S, Fricker FJ, Jaffe R, Demmler G, Kearney D, Zhang YH, Bodurtha J, Gelb B, Ni J, et al (1994) Acute myocarditis. Rapid diagnosis by PCR in children. Circulation 90:330-339
46. Martino TA, Petric M, Brown M, Aitken K, Gauntt CJ, Richardson CD, Chow LH, Liu PP (1998) Cardiovirulent coxsackieviruses and the decay-accelerating factor (CD55) receptor. Virology 244:302-314
47. McCarthy RE 3rd, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM, Baughman KL (2000) Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342:690-695
48. McKnight A, Weiss RA (2003) Blocking the docking of HIV-1. Proc Natl Acad Sci U S A 100:10581-10582
49. McManus BM, Chow LH, Wilson JE, Anderson DR, Gulizia JM, Gauntt CJ, Klingel KE, Beisel KW, Kandolf R (1993) Direct myocardial injury by enterovirus: a central role in the evolution of murine myocarditis. Clin Immunol Immunopathol 68:159-169
50. McManus BM, Yanagawa B, Rezai N, Luo H, Taylor L, Zhang M, Yuan J, Buckley J, Triche T, Schreiner G, Yang D (2002) Genetic determinants of coxsackievirus B3 pathogenesis. Ann N Y Acad Sci 975:169-179
51. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, Hilton DJ, Alexander WS (2000) Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 405:1069-1073
52. Morens DM, Folkers GK, Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430:242-249
53. Nomura H, Tanimoto H, Kajiwara E, Shimono J, Maruyama T, Yamashita N, Nagano M, Higashi M, Mukai T, Matsui Y, Hayashi J, Kashiwagi S, Ishibashi H (2004) Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 19:1312-1317
54. Offensperger WB, Offensperger S, Walter E, Teubner K, Igloi G, Blum HE, Gerok W (1993) In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligodeoxynucleotides. EMBO J 12:1257-1262
55. Opavsky MA, Martino T, Rabinovitch M, Penninger J, Richardson C, Petric M, Trinidad C, Butcher L, Chan J, Liu PP (2002) Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest 109:1561-1569
56. Parks WC, Wilson CL, Lopez-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617-629
57. Pauschinger M, Rutschow S, Chandrasekharan K, Westermann D, Weitz A, Peter Schwimmbeck L, Zeichhardt H, Poller W, Noutsias M, Li J, Schultheiss HP, Tschope C (2005) Carvedilol improves left ventricular function in murine coxsackievirus-induced acute myocarditis association with reduced myocardial interleukin-1beta and MMP-8 expression and a modulated immune response. Eur J Heart Fail 7:444-452
58. Rosas MF, Martinez-Salas E, Sobrino F (2003) Stable expression of antisense RNAs targeted to the 5′ non-coding region confers heterotypic inhibition to foot-and-mouth disease virus infection. J Gen Virol 84:393-402
59. Rotbart HA (2002) Treatment of picornavirus infections. Antiviral Res 53:83-98
60. Sawyer MH (2002) Enterovirus infections: diagnosis and treatment. Semin Pediatr Infect Dis 13:40-47
61. Schmidtke M, Hammerschmidt E, Schüler S, Zell R, Birch-Hirschfeld E, Makarov VA, Riabova OB, Wutzler P (2005) Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother 56:648-656
62. Selinka HC, Wolde A, Pasch A, Klingel K, Schnorr JJ, Küpper JH, Lindberg AM, Kandolf R (2002) Comparative analysis of two coxsackievirus B3 strains: putative influence of virusreceptor interactions on pathogenesis. J Med Virol 67:224-233
63. Si X, Luo H, Morgan A, Zhang J, Wong J, Yuan J, Esfandiarei M, Gao G, Cheung C, McManus BM (2005a) Stress-activated protein kinases are involved in coxsackievirus B3 viral progeny release. J Virol 79:13875-13881
64. Si X, McManus BM, Zhang J, Yuan J, Cheung C, Esfandiarei M, Suarez A, Morgan A, Luo H (2005a) Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol 79:8014-8023
65. Sidwell RW, Robins RK, Hillyard IW (1979) Ribavirin: an antiviral agent. Pharmacol Ther 6:123-146
66. Stein J, Liang P (2002) Differential display technology: a general guide. Cell Mol Life Sci 59:1235-1240
67. Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92:827-839
68. Wang A, Cheung PK, Zhang H, Carthy CM, Bohunek L, Wilson JE, McManus BM, Yang D (2001) Specific inhibition of coxsackievirus B3 translation and replication by phosphorothioate antisense oligodeoxynucleotides. Antimicrob Agents Chemother 45:1043-1052
69. Yanagawa B, Spiller OB, Choy J, Luo H, Cheung P, Zhang HM, Goodfellow IG, Evans DJ, Suarez A, Yang D, McManus BM (2003) Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice. Lab Invest 83:75-85
70. Yanagawa B, Spiller OB, Proctor DG, Choy J, Luo H, Zhang HM, Suarez A, Yang D, McManus BM (2004) Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice. J Infect Dis 189:1431-1439
71. Yang D, Wilson JE, Anderson DR, Bohunek L, Cordeiro C, Kandolf R, McManus BM (1997) In vitro mutational and inhibitory analysis of the cis-acting translational elements within the 5′ untranslated region of coxsackievirus B3: potential targets for antiviral action of antisense oligomers. Virology 228:63-73
72. Yang D, Yu J, Luo Z, Carthy CM, Wilson JE, Liu Z, McManus BM (1999) Viral myocarditis: identification of five differentially expressed genes in coxsackievirus B3-infected mouse heart. Circ Res 84:704-712
73. Yasukawa H, Yajima T, Duplain H, Iwatate M, Kido M, Hoshijima M, Weitzman MD, Nakamura T, Woodard S, Xiong D, Yoshimura A, Chien KR, Knowlton KU (2003) The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J Clin Invest 111:469-478
74. Yuan J, Cheung PK, Zhang H, Chau D, Yanagawa B, Cheung C, Luo H, Wang Y, Suarez A, McManus BM, Yang D (2004) A phosphorothioate antisense oligodeoxynucleotide specifically inhibits coxsackievirus B3 replication in cardiomyocytes and mouse hearts. Lab Invest 84:703-714
75. Yuan J, Zhang J, Wong BW, Si X, Wong J, Yang D, Luo H (2005a) Inhibition of glycogen synthase kinase 3beta suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of beta-catenin. Cell Death Differ 12:1097-1106
76. Yuan J, Cheung PK, Zhang HM, Chau D, Yang D (2005b) Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand. J Virol 79:2151-2159
77. Yuan JP, Zhao W, Wang HT, Wu KY, Li T, Guo XK, Tong SQ (2003) Coxsackievirus B3-induced apoptosis and caspase-3. Cell Res 13:203-209
78. Zautner AE, Jahn B, Hammerschmidt E, Wutzler P, Schmidtke M (2006) N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J Virol 80:6629-6636
79. Zhang HM, Yanagawa B, Cheung P, Luo H, Yuan J, Chau D, Wang A, Bohunek L, Wilson JE, McManus BM, Yang D (2002) Nip21 gene expression reduces coxsackievirus B3 replication by promoting apoptotic cell death via a mitochondria-dependent pathway. Circ Res 90:1251-1258
80. Zhao Q, Zhou R, Temsamani J, Zhang Z, Roskey A, Agrawal S (1998) Cellular distribution of phosphorothioate oligonucleotide following intravenous administration in mice. Antisense Nucleic Acid Drug Dev 8:451-458